Welcome to our dedicated page for DALRADA FINCL news (Ticker: DFCO), a resource for investors and traders seeking the latest updates and insights on DALRADA FINCL stock.
Dalrada Financial Corporation, through its subsidiaries, provides various products and services in the manufacturing, engineering, and healthcare sectors worldwide. The company offers low-carbon heating and cooling systems, visual inspection kits for detecting cervical cancer, and software solutions in test engineering, accessibility engineering, and more. Additionally, it provides cleaning solutions with electrostatic machines for various facilities. Formerly known as Imaging Technologies Corporation, Dalrada Financial Corporation was incorporated in 1982 and is headquartered in Escondido, California.
The company, under the leadership of CEO Brian Bonar, focuses on driving innovation in the Clean Energy and Health Care sectors. Its segments include Dalrada Climate Technology and Genefic Specialty Pharmacy, offering advanced heat pump technology and end-to-end prescription services, respectively. With a commitment to sustainability and cutting-edge solutions, Dalrada Financial Corporation aims to deliver value to its shareholders.
Dalrada Corporation (DFCO) announced a securities purchase agreement for issuing convertible debentures totaling $3,000,000. The first debenture valued at $2,000,000 was acquired on February 7, 2022, while the second, worth $1,000,000, will follow after a registration statement with the SEC. The financing supports Dalrada’s expansion in key growth markets including Technology, Energy, and Health, particularly enhancing its Empower Genomics and Likido Limited subsidiaries.
Dalrada Corporation (OTCQB: DFCO) appreciates its investors and staff for their support in 2021, highlighting significant expansions into clean energy, healthcare, and technology. The company has reported impressive growth metrics, including a 189% year-over-year revenue increase and a 506% quarter-to-quarter revenue surge as of September 30, 2021. Additionally, Dalrada aims to tackle global challenges through impactful innovations across its subsidiaries. With a focus on digital transformation and personalized healthcare, Dalrada is well-positioned for future growth in the evolving market landscape.
Dalrada Corporation (OTCQB: DFCO) collaborates with Lenovo and Iceotope to develop an ultra-low power, liquid-cooled technology for data centers. This new system aims to address environmental concerns by recycling excess heat for district heating, providing a dual benefit of energy cost savings and creating new revenue streams. By utilizing Likido®AD absorption chillers, the partnership promises ultra-low power usage effectiveness (PUE) ratios, transforming data center operations while reducing water and energy consumption. The global liquid cooling market is projected to grow significantly, indicating strong industry demand.
Dalrada Corporation (DFCO) has announced the addition of two new directors, Amy Wing Scannell, Esq., and Vincent Monteparte, to its Board of Directors. Scannell brings expertise in corporate compliance and investments, while Monteparte has extensive experience in venture capital and investment banking, managing significant transactions. CEO Brian Bonar emphasized the strategic importance of these appointments as Dalrada prepares to expand into high-growth sectors and plans to uplist to NASDAQ, aiming to strengthen its market position and governance.
Dalrada Corporation (OTCQB: DFCO) has appointed Harvey Hershkowitz as President of its subsidiary, Dalrada Health. With over 35 years in the healthcare sector, his experience is expected to bolster the company’s growth and expansion initiatives. Dalrada Health is involved in multiple segments, including GlanHealth™ and Pala Diagnostics, and has achieved significant milestones in healthcare services, including the launch of COVID-19 on-site testing. The global healthcare services market is projected to grow at a CAGR of 7% to $9,725.4 billion by 2023, positioning Dalrada favorably in this evolving landscape.
Dalrada Corporation (DFCO) has reported impressive financial results for Q1 ending September 30, 2021, with revenues of $4,602,353, a remarkable 506% increase from $759,393 in Q1 2020. Gross profit surged to $3,398,018, up 546% from $525,965 the previous year. The stockholder deficit decreased by 48%. Dalrada's strong performance comes alongside growth in its healthcare and technology divisions, despite increased operating expenses due to various expansions and compensations.
Dalrada Corporation (OTCQB: DFCO) announces the opening of two new healthcare facilities in California, including the Sòlas Rejuvenation + Wellness clinic and Empower Genomics laboratory. These facilities aim to enhance public access to personalized health solutions and virology testing, including on-site COVID-19 testing. Sòlas offers a range of advanced medical and therapy services in a 56,510-square foot center in Poway, California. The company emphasizes its commitment to addressing global health challenges through innovative solutions and partnerships.
Dalrada Corporation (OTCQB: DFCO) announced the authorization of 10,002 Convertible Series “G” Preferred Shares at a par value of $0.01 each on September 23. This move will convert $6,532,188 from liabilities to Owner’s Equity. The investors agreed to waive penalties and default interest after September 30, 2021. This transaction indicates a positive shift in equity management. Dalrada has made significant advances in technology, engineering, and health sectors, enhancing revenues and operating profits during fiscal year 2021. The company aims to provide innovative solutions across its three divisions.
Dalrada Corporation (DFCO) has signed a letter of intent to acquire Advanced DME Services, also known as Advanced Homecare, a Southern California-based provider focusing on sleep apnea solutions. This strategic acquisition aims to establish a new subsidiary within Dalrada Health, expanding its market reach and enhancing growth opportunities. Advanced Homecare has served nearly 40,000 patients since 2005, and its revenue reached $10 million in 2020. The acquisition aligns with Dalrada's mission to improve healthcare solutions and is backed by coverage from major insurance providers.
Dalrada Corporation (DFCO) has been recognized as one of the Best San Diego-Based Clean Energy Companies. The company aims to innovate solutions for complex problems in clean energy, industrial engineering, health, and wellness. Dalrada's subsidiary, Likido®, received accolades for its innovation and societal impact. Likido® energy solutions focus on reducing greenhouse gas emissions and improving energy efficiency, with products like Likido®ONE and Likido®CRYO. The company emphasizes corporate social responsibility and environmental stewardship.
FAQ
What is the current stock price of DALRADA FINCL (DFCO)?
What is the market cap of DALRADA FINCL (DFCO)?
What products and services does Dalrada Financial Corporation offer?
When was Dalrada Financial Corporation incorporated?
Where is Dalrada Financial Corporation headquartered?
Who is the CEO of Dalrada Financial Corporation?
What are the core segments of Dalrada Financial Corporation?
What is the focus of Dalrada Financial Corporation?
What is the mission of Dalrada Financial Corporation?
